Patent · US Active

Destruction of tumor cells by trifunctional bispecific antibodies with low to medium expression levels of tumor-associated target antigens

US9017676B2 · kind B2 · utility

28Cited by

1References

18Claims

0Family size

Assignee

Horst Lindhofer · DE

Inventor

Horst Lindhofer · Puchheim, DE

Key dates

Filing date	Feb 15, 2007
Grant date	Apr 28, 2015
Priority date	—
Expiry date	Feb 5, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The use of trifunctional bispecific antibodies for the preparation of a pharmaceutical composition for the prophylaxis and treatment of tumor diseases is provided. Trifunctional bispecific antibodies bind to tumor-associated antigens including Her2/neu, CD20, EpCAM, G250, proteoglycans, GD3. GD2, MHC II, EGF-R and CEA expressed on tumor cells at low to medium expression levels. Also provided are methods for the treatment or prophylaxis of tumor diseases by administering a pharmaceutically effective amount of a trifunctional bispecific antibody to a patient in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.